Patents Examined by Lisa B. Arthur
  • Patent number: 6372430
    Abstract: Nucleic acids for detecting Aspergillus species and other filamentous fungi are provided. Unique internal transcribed space 2 coding regions permit the development of nucleic acid probes specific for five different species of Aspergillus, three species of Fusarium, four species of Mucor, two species of Penecillium, five species of Rhizopus, one species of Rhizomucor, as well as probes for Absidia corymbifer, Cunninghamella elagans, Pseudallescheria boydii, and Sporothrix schenkii. Methods are disclosed for the species-specific detection and diagnosis of infection by Aspergillus, Fusarium, Mucor, Penecillium, Rhizomucor, absidia, Cunninghaemella, Pseudallescheria or Sporthrix in a subject. Furthermore, genus-specific probes are also provided for Aspergillus, Fusarium and Mucor, in addition to an all-fungus nucleic acid probe.
    Type: Grant
    Filed: June 27, 2000
    Date of Patent: April 16, 2002
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Christine J. Morrison, Errol Reiss, Liliana Aidorevich, Jong Soo Choi
  • Patent number: 6368855
    Abstract: Disclosed is a specific regulator of Ii protein expression or immunoregulatory function. Specifically disclosed are several forms of the specific regulator of Ii, including those which function through the formation of a duplex molecule with an RNA molecule encoding mammalian Ii protein to inhibit Ii protein synthesis at the translation level. This class includes copolymers comprised of nucleotide bases which hybridize specifically to the RNA molecule encoding mammalian Ii protein, and also expressible reverse gene constructs. In other aspects, the disclosure relates to MHC class II-positive antigen presenting cells containing a specific regulator of Ii expression. Such cells are useful, for example, in the display of autodeterminant peptides in association with MHC class II proteins. Compositions of the invention find application in methods for treating diseases, for example malignancies and autoimmune disorders, in a patient by enhancing immunological attack on undesired cells.
    Type: Grant
    Filed: December 4, 1998
    Date of Patent: April 9, 2002
    Assignee: Antigen Express, Inc.
    Inventors: Minzhen Xu, Gang Qiu, Robert Humphreys
  • Patent number: 6342350
    Abstract: The disclosed invention relates to a diagnostic method for Alzheimer's disease based on genotyping the Alpha-2-Macroglobulin locus. A statistically significant correlation was found between inheritance of particular alleles of the Alpha-2-Macroglobulin gene and the occurrence of Alzheimer's disease. The diagnostic method involves the isolation of nucleic acid from an individual and subsequent genotyping by means such as sequencing or restriction fragment length polymorphism analysis. The invention also provides a means of genotype analysis through protein isotyping Alpha-2-Macroglobulin variant proteins. Finally, kits for nucleic acid analysis or protein analysis are taught.
    Type: Grant
    Filed: September 4, 1998
    Date of Patent: January 29, 2002
    Assignee: The General Hospital Corporation
    Inventors: Rudolph E. Tanzi, Bradley T. Hyman, George W. Rebeck, Deborah L. Blacker
  • Patent number: 6340563
    Abstract: A method for topographic genotyping is described. The method comprises the steps of placing a biological specimen having DNA of a patient under a microscope. Then there is the step of inspecting the biological specimen microscopically with the microscope. Next there is the step of choosing a microscope size target on the biological specimen based on its histopathologic characteristics. Next there is the step of separating the target from the specimen. Then there is the step of obtaining DNA sequences from the target so the DNA sequences can be amplified. Next there is the step of amplifying the DNA sequences. Then there is the step of detecting mutations in the DNA sequences. More specifically, the method comprises the steps of separating a section from a specimen of fixative treated tissue. Then there is the step of obtaining DNA sequences from the section.
    Type: Grant
    Filed: June 24, 1996
    Date of Patent: January 22, 2002
    Inventors: Sydney David Finkelstein, Patricia Anne Finkelstein
  • Patent number: 6337207
    Abstract: Provided herein are variant alleles of a gene encoding a mu opioid receptor, along with cloning vectors for replicating such variant alleles, expressing vectors for expressing the variant alleles to produce variant mu opioid receptors, and antibodies to such variant receptors. Also disclosed are binding characteristics of such variant receptors regarding binding to opioid ligands, and the using of such binding characteristics to diagnose a subjects susceptibility to pain, susceptibility to an addictive disease, selecting an appropriate pain reliever along with a therapeutically effective amount of the reliever to administer to a subject suffering from pain. In addition, diagnostic methods for diagnosing a disease or disorder such as infertility, constipation, diarrhea, decreased immune response relative to a standard, and decreased ability to withstand stress relative to a standard, along with commercial kits for diagnosing such diseases or disorders.
    Type: Grant
    Filed: July 10, 1998
    Date of Patent: January 8, 2002
    Assignees: The Rockefeller University, The Advanced Research and Technology Institute, Inc.
    Inventors: Mary Jeanne Kreek, Karl Steven LaForge, Lei Yu, Jay A. Tischfield
  • Patent number: 6331393
    Abstract: There is disclosed an improved high-throughput and quantitative process for determining methylation patterns in genomic DNA samples based on amplifying modified nucleic acid, and detecting methylated nucleic acid based on amplification-dependent displacement of specifically annealed hybridization probes. Specifically, the inventive process provides for treating genomic DNA samples with sodium bisulfite to create methylation-dependent sequence differences, followed by detection with fluorescence-based quantitative PCR techniques. The process is particularly well suited for the rapid analysis of a large number of nucleic acid samples, such as those from collections of tumor tissues.
    Type: Grant
    Filed: May 14, 1999
    Date of Patent: December 18, 2001
    Assignee: University of Southern California
    Inventors: Peter W. Laird, Cindy A. Eads, Kathleen D. Danenberg
  • Patent number: 6329149
    Abstract: Teeth, the hardest substance in the human body, are frequently all that remain of a mortuary population from which direct human presence can be gleaned. As such their morphology is invaluable to physical anthropologists and investigators in allied disciplines. Methods currently used for purposes of extracting DNA from dental remains—e.g. bone-milling, crushing, and sectioning—result in total destruction of the teeth. This paper introduces the Reverse-Root-Canal, a protocol by which DNA of molecular weight higher than that obtainable through traditional destructive means, can be obtained from ancient dental remains without harm to the morphologically informative crown and roots.
    Type: Grant
    Filed: March 7, 2000
    Date of Patent: December 11, 2001
    Inventor: Janice Cori Cobb
  • Patent number: 6326148
    Abstract: The present invention provides methods of screening for colon carcinoma cells in a sample. The methods comprise providing a nucleic acid sample from a premalignant lesion in colorectal tissue from a human patient and contacting the sample with a nucleic acid probe that selectively hybridizes to a chromosomal region at 20q.
    Type: Grant
    Filed: July 12, 1999
    Date of Patent: December 4, 2001
    Assignee: The Regents of the University of California
    Inventors: Giovanni E. Pauletti, Dennis J. Slamon
  • Patent number: 6323335
    Abstract: The present invention provides mammalian retinoblastoma (Rb) protein-interacting zinc finger (RIZ) proteins, nucleic acid molecules encoding RIZ and antibodies specific for RIZ. The invention provides methods for identifying an agent that alters the association of a RIZ with a second molecule, which can bind to RIZ. The invention provides fragments of RIZ, PRD1-BF1, EVI-1, and egl-43. The invention provides methods for introducing a nucleic acid molecule encoding a RIZ into a cell and for contacting a cell with an effective agent in order to modulate a function of a cell. The invention further provides methods for detecting a RIZ in a sample by detecting RIZ or a nucleic acid molecule encoding RIZ.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: November 27, 2001
    Inventor: Shi Huang
  • Patent number: 6319535
    Abstract: An edible confection with a recognizable shape which repeatedly rises and sinks, i.e., “swims,” in a transparent carbonated beverage due to changing buoyancy resulting from the formation of carbonation bubbles on the surface of the confection, and the escape of the bubbles to the atmosphere when the confection reaches the top of the beverage. The ability of the confection to ascend and descend is determined by the density, volume and surface area of the confection, and the volume per unit surface area of bubbles which form on the confection. For a thin confection the conditions for ascension and descension are substantially independent of the dimensions other than the thickness. Bubble nucleation is promoted by a surface which is rough on small length scales, and large bubbles can be retained on the surface if the confection is smooth on larger length scales.
    Type: Grant
    Filed: October 28, 1999
    Date of Patent: November 20, 2001
    Inventor: Laurence J. Shaw
  • Patent number: 6316195
    Abstract: Karnal bunt of wheat is caused by Tilletia indica Mitra. Recently, teliospores morphologically resembling T. indica were isolated from bunted ryegrass seeds and wheat seed washes. Previously developed PCR assays failed to differentiate T. indica from the newly discovered ryegrass pathogen, T. walkeri. The nucleotide sequence of a 2.3-kb region of mitochondrial DNA, previously amplified by PCR only from T. indica, was determined for three isolates of T. indica and for three isolates of T. walkeri. There was greater than 99% identity within either the T. indica group or the T. walkeri group of isolates, whereas there was approximately 3% divergence between isolates of these two Tilletia species. Five sets of PCR primers were made specific to T. indica, and three sets were designed specifically for T. walkeri based upon nucleotide differences within the mtDNA region.
    Type: Grant
    Filed: December 23, 1999
    Date of Patent: November 13, 2001
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Reid D. Frederick, Paul W. Tooley, Morris R. Bonde, David A. Knorr, Gary L. Peterson, Norman W. Schaad
  • Patent number: 6309819
    Abstract: The present invention relates to a diagnostic system for the detection of Crohn's disease and ulcerative colitis by means of nucleotide amplification reactions, in situ or in vitro which detection means are specific for the measles virus and are capable of distinguishing between the “wild” type and the attenuated measles virus strains. The invention further provides a use in the manufacture of a medicament for the treatment of Crohn's disease and/or ulcerative colitis which medicament comprises a suitable vector carrying antisense RNA to specific viral proteins which are consequently inhibited from being expressed in the host.
    Type: Grant
    Filed: October 23, 1997
    Date of Patent: October 30, 2001
    Inventor: Andrew Jeremy Wakefield
  • Patent number: 6306596
    Abstract: Methods, employing a nucleotide integrase, for cleaving single-stranded RNA substrates, single-stranded DNA substrates, and double-stranded DNA substrates at specific sites and for inserting a nucleic acid molecule into the cleaved substrate are provided. One method uses a nucleotide integrase to cleave one strand of a double-stranded DNA substrate. The method comprises the steps of: providing an isolated nucleotide integrase comprising a group II intron RNA having two hybridizing sequences for hybridizing with two intron RNA binding sequences on the top strand of the DNA substrate, and a group II-intron encoded protein which binds to a first sequence element of the substrate; and reacting the nucleotide integrase with the double-stranded DNA substrate to permit the nucleotide integrase to cleave the top strand of the DNA substrate and to insert the group II intron RNA into the cleavage site.
    Type: Grant
    Filed: February 25, 1999
    Date of Patent: October 23, 2001
    Assignee: The Ohio State University Research Foundation
    Inventors: Allen M. Lambowitz, Steven Zimmerly, Huatao Guo, Georg Mohr, Clifford James Beall
  • Patent number: 6303307
    Abstract: The present invention provides a method of screening individuals at risk for developing diseases caused by trinucleotide repeat sequence instability. Specifically, the present invention is drawn to screening individuals at risk for developing autosomal dominant spinocerebellar ataxia type 6 by determining the length of a CAG trinucleotide repeat in the &agr;1A calcium channel gene of the individual. In addition, there is provided a method of identifying genes which are disease-causing due to trinucleotide repeat sequence instability by large scale genotyping.
    Type: Grant
    Filed: April 23, 1999
    Date of Patent: October 16, 2001
    Assignee: Research Development Foundation
    Inventor: Cheng-Chi Lee
  • Patent number: 6297014
    Abstract: In a method for detecting a genetic predisposition in a human for non-responsiveness to statin drug treatment for coronary artery disease, nucleic acids comprising nucleotide sequences of the human lipoprotein lipase (LPL) gene are amplified and analyzed. Homozygosity for a variant allele in a non-coding or untranslated region of the 3′ end of LPL, for example, LPL HindIII 2/2 or (TTTA)n 4/4 genotypes, is linked to non-responsiveness to treatment with statin drugs, including lovastatin, pravastatin, simvastatin, atorvastatin, fluvastatin, or cerivastatin. Oligonucleotide primer sequences, primer sets, and genetic testing kits allow the practitioner to practice the method and thus better individualize the treatment and improve the care of patients with coronary artery disease.
    Type: Grant
    Filed: July 2, 1999
    Date of Patent: October 2, 2001
    Assignee: Cedars-Sinai Medical Center
    Inventors: Kent D. Taylor, Maren T. Scheuner, Jerome I. Rotter, Huiying Yang
  • Patent number: 6297010
    Abstract: This invention provides various methods for identifying one or more genetic alterations in a sample polynucleotide strand.
    Type: Grant
    Filed: January 30, 1998
    Date of Patent: October 2, 2001
    Assignee: Genzyme Corporation
    Inventor: James E. Stefano
  • Patent number: 6287779
    Abstract: Unique DNA sequences characteristic of fermentation-related microorganisms are provided which are useful as primers in PCR-based analysis for identification of fermentation-related microorganisms
    Type: Grant
    Filed: January 20, 2000
    Date of Patent: September 11, 2001
    Assignee: E. & J. Gallo Winery
    Inventors: Stacia R. Engel, Richard A. Morenzoni, Nancy A. Irelan
  • Patent number: 6280930
    Abstract: The present invention relates to a method for amplifying and detecting a target nucleic acid. The method comprising contacting a sample suspected of containing the target nucleic acid with a thermostable DNA polymerase and two primers that are substantially complementary to the target nucleic acid, under conditions such that the target nucleic acid is amplified. The amplified target nucleic acids are then denatured to form single stranded nucleic acids. Following amplification, the sample is subject to a pre-detection incubation step. The sample is incubated for between 1 second and 30 minutes at between 95° C. and 120° C. to inactivate said polymerization agent. Finally, the presence or absence of the amplified target nucleic acids is determined. Preferably, amplification, incubation and detection are carried out in a closed reaction vessel.
    Type: Grant
    Filed: April 25, 1997
    Date of Patent: August 28, 2001
    Assignee: Johnson & Johnson Clinical Diagnostics, Inc.
    Inventors: John W. Backus, Marcia L. Kramer, Joseph Falvo
  • Patent number: 6280951
    Abstract: A method for predicting reactivity to parathyroid hormone by determining the genotype with respect to polymorphism in the parathyroid hormone receptor gene. The results obtained by the analysis of genetic polymophism are useful for predicting the tendency for a hemodialyzed patient to develop severe secondary hyperparathyroidism, or for predicting the tendency for a human individual to develop severe primary hyperparathyroidism. Also, this method is useful for predicting the therapeutic effects by predicting reactivity to parathyroid hormone in a patient who is being treated for regressive osteoporosis by administration of parathyroid hormone.
    Type: Grant
    Filed: March 8, 2000
    Date of Patent: August 28, 2001
    Assignees: Sumikin Bio-Science, Inc.
    Inventors: Masayuki Heishi, Osamu Ishida, Hiromitsu Tazawa, Yusuke Tsukamoto
  • Patent number: 6277563
    Abstract: The present invention provides new probes for the detection of chromosomal alterations associated with cancer, particularly ovarian cancer. The probes bind selectively with target nucleic acid sequences at 3q26.
    Type: Grant
    Filed: January 16, 1997
    Date of Patent: August 21, 2001
    Assignee: The Regents of the University of California
    Inventors: Laleh Shayesteh, Joe W. Gray